Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
Regen BioPharma, Inc. extends a warm welcome to both individual and institutional investors, as well as advisors and analysts, to participate in its live and engaging presentation at the Emerging Growth Conference.
Regen BioPharma, Inc., a biotech firm that is making strides in the field of advanced biological products, will have the opportunity to showcase its extensive range of pre-clinical projects at the upcoming Emerging Growth Conference. This conference, scheduled for August 10, 2023, will provide a platform for Regen BioPharma, Inc. to present their ongoing work in cell treatments, RNA immunizations, RNA and DNA treatments, as well as small molecule pharmaceuticals. To learn more about the conference, visit https://emerginggrowth.com/conference/.
This exciting, interactive online event will allow current shareholders and the investment community to engage with the Company's CEO, Dr. David Koos, in the moment. Feel free to ask your questions during the event, and Dr. Koos and his team will make every effort to address as many of them as they can.
Dr. David Koos, the Company's Chairman and CEO, states that during this period, they aim to provide their stakeholders with updates regarding their future funding and operational plans, the progress of their research program, and address any inquiries from shareholders.
Regen BioPharma, Inc. is scheduled to make a presentation on Thursday, August 10, 2023, between 11:25 AM and 11:55 AM Eastern time. To secure your attendance at the conference and stay updated with any new information, kindly register through the following link: https://goto.webcasts.com/starthere.jsp?ei=1603283&tp_key=7656c5070a&sti=rgbp
If participants cannot attend the live event on the conference day, they can still access a recorded webcast on EmergingGrowth.com.
Introducing the Emerging Growth Conference:The Emerging Growth conference offers a convenient and time-saving platform for public companies to showcase and share their latest offerings, such as new products, services, and important updates, with the investment community. Instead of physically attending events, companies can effortlessly connect with potential investors right from the comfort of their own office space.
The blog section is dedicated to highlighting businesses from various industries that are experiencing growth. These companies have competent leaders and offer unique and forward-thinking products and services. They possess a well-defined strategy and exemplary execution, indicating their potential for sustained growth. The blog attracts a large readership comprising both individual and institutional investors, investment advisors, and analysts.
Regen BioPharma Inc. is a biotechnology company that can be publicly traded. The company's main focus is on immunology and immunotherapy. They are determined to make progress in new and exciting technologies by conducting tests before clinical trials. At the moment, Regen BioPharma is concentrating on developing mRNA and small molecule therapies to treat cancer and autoimmune disorders. If you want to find out more about Regen BioPharma, you can visit their website at www.regenbiopharmainc.com.
Please note: This news update might include statements about future expectations. These statements are inherently uncertain and involve unknown factors that cannot be accurately predicted. Actual results may differ significantly from what is expressed or implied in the forward-looking statements. The risks and uncertainties associated with such statements include, but are not limited to, the impact of government regulations, competition, and various other significant risks.
Regen BioPharma Inc. David R. Koos, Ph.D. Head Honcho & Top Boss Contact Number: +1-619-722-5505 Fax Number: +1-619-330-2328 Email Address: [email protected]
Stay connected with us on Twitter to receive all the latest updates: https://twitter.com/TheRegenBio
Regen BioPharma, Inc. is the original source of the information provided in this blog.
